Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)

Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’

Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores

DGHS, Health Ministry, along with experts reviews the Chandipura virus and AES cases in states

Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases

Elucid appoints Kelly Huang as CEO

Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software

Lupin divests US commercial women's health specialty business to Evofem

Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024

Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain

Merck completes acquisition of EyeBio

Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret

Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%

The approved ANDA is therapeutically equivalent to the reference listed drug product